Beta Drugs Ltd

Why is Beta Drugs Ltd falling/rising?

As of 24-Aug, Beta Drugs Ltd's stock price is at 2,307.00, down 0.89%, primarily due to a significant drop in investor participation and underperformance compared to the benchmark Sensex. Despite strong fundamentals, negative market sentiment and short-term price momentum weakness are contributing to the stock's decline.

As of 24-Aug, Beta Drugs Ltd's stock price is falling, currently at 2,307.00, reflecting a decrease of 20.7 points or 0.89%. This decline can be attributed to several factors highlighted in the performance metrics. Over the past week, the stock has underperformed, showing a drop of 5.17%, while the benchmark Sensex only fell by 0.28%. Additionally, the stock has experienced a significant reduction in investor participation, with delivery volume on August 21 falling by 45.64% compared to the 5-day average. <BR><BR>Despite the company's strong fundamentals, including a low Debt to EBITDA ratio and positive quarterly results, the current market sentiment appears to be negative, as indicated by the stock's performance today, which underperformed its sector by 0.8%. Furthermore, while the stock remains above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting a short-term weakness in price momentum. Overall, these factors contribute to the current downward trend in Beta Drugs Ltd's stock price.

Which are the latest news on Beta Drugs Ltd?

Who are in the management team of Beta Drugs Ltd?

The management team of Beta Drugs Ltd includes Rahul Batra (Chairperson & Managing Director), Varun Batra (Joint Managing Director), Balwant Singh, Seema Chopra, and Ashutosh Shukla (Whole-time Directors), along with Independent Directors Manmohan Khanna and Rohit Parti, and Rajni Brar (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Beta Drugs Ltd includes the following individuals:<BR><BR>1. **Rahul Batra** - Chairperson & Managing Director<BR>2. **Varun Batra** - Joint Managing Director<BR>3. **Balwant Singh** - Whole-time Director<BR>4. **Seema Chopra** - Whole-time Director<BR>5. **Ashutosh Shukla** - Whole-time Director<BR>6. **Manmohan Khanna** - Independent Director<BR>7. **Rohit Parti** - Independent Director<BR>8. **Rajni Brar** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Beta Drugs Ltd do?

Beta Drugs Ltd is a micro-cap pharmaceutical and biotechnology company, incorporated in 2005 and public since 2017, with recent net sales of 126 Cr and net profit of 16 Cr as of June 2026. The company has a market cap of INR 2,893 Cr and key financial metrics include a P/E of 63.00 and a debt-equity ratio of 0.09.

Overview:<BR>Beta Drugs Ltd is a pharmaceutical and biotechnology company operating in the micro-cap market.<BR><BR>History:<BR>Beta Drugs Ltd was incorporated as a private limited company in 2005 and later converted into a public limited company in 2017. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 126 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 16 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 2,893 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 63.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.09 <BR>Return on Equity: 16.95% <BR>Price to Book: 11.59 <BR><BR>Contact Details:<BR>Address: Village Nandpur, Baddi Himachal Pradesh: 174101 <BR>Phone: 91-1795-236196 <BR>Email: info@betadrugslimited.com <BR>Website: http://www.betadrugslimited.com

Who are the peers of the Beta Drugs Ltd?

Beta Drugs Ltd's peers include Unichem Labs, SMS Pharma, Advanced Enzyme, Kwality Pharma, Dishman Carbogen, Hikal, Ind-Swift Labs, Solara Active, and Panacea Biotec. In terms of management risk, growth, and capital structure, Beta Drugs Ltd is rated average, with a 1-year return of 33.76%.

Peers: The peers of Beta Drugs Ltd are Unichem Labs., SMS Pharma., Advanced Enzyme, Kwality Pharma, Dishman Carbogen, Hikal, Ind-Swift Labs., Solara Active, and Panacea Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Advanced Enzyme and Kwality Pharma, while Average management risk is found at Unichem Labs., SMS Pharma, Beta Drugs Ltd, and Hikal. Below Average management risk is noted for Dishman Carbogen, Ind-Swift Labs., Solara Active, and Panacea Biotec. Growth is rated as Good for Unichem Labs. and Dishman Carbogen, Average for Beta Drugs Ltd, and Below Average for SMS Pharma, Advanced Enzyme, Kwality Pharma, Hikal, Ind-Swift Labs., Solara Active, and Panacea Biotec. Capital Structure is Excellent for Advanced Enzyme and Kwality Pharma, Good for Unichem Labs., Average for SMS Pharma and Ind-Swift Labs., and Below Average for Dishman Carbogen, Hikal, Solara Active, and Panacea Biotec.<BR><BR>Return Snapshot: Ind-Swift Labs. has the highest 1-year return at 180.93%, while Advanced Enzyme has the lowest at -1.99%. Beta Drugs Ltd's 1-year return is 33.76%, which is significantly higher than Advanced Enzyme's but lower than Ind-Swift Labs. Additionally, Dishman Carbogen, Hikal, Solara Active, and Panacea Biotec all have negative six-month returns.

How big is Beta Drugs Ltd?

As of 14th August, Beta Drugs Ltd has a market capitalization of 2,820.36 Cr, with recent net sales of 410.17 Cr and a net profit of 45.59 Cr. Shareholder's funds are 197.10 Cr, and total assets are valued at 434.41 Cr as of March 2025.

As of 14th August, Beta Drugs Ltd has a market capitalization of 2,820.36 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Beta Drugs Ltd reported Net Sales of 410.17 Cr and a Net Profit of 45.59 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 197.10 Cr and Total Assets valued at 434.41 Cr.

Are Beta Drugs Ltd latest results good or bad?

Beta Drugs Ltd's latest Q1 FY27 results are strong, with revenue of ₹125.55 crores (up 33.62% QoQ and 25.29% YoY) and a net profit of ₹15.80 crores (up 74.59% QoQ and 35.04% YoY), indicating robust growth and improved profitability. The company also achieved a high operating margin of 21.80% and a return on equity of 53.00%, positioning it well in the pharmaceutical sector.

Beta Drugs Ltd's latest results for Q1 FY27 are quite strong and can be considered good. The company reported a revenue of ₹125.55 crores, which reflects a robust growth of 33.62% quarter-on-quarter and 25.29% year-on-year. This is the highest quarterly revenue in its recent history.<BR><BR>Moreover, the net profit surged to ₹15.80 crores, marking a remarkable increase of 74.59% from the previous quarter and 35.04% year-on-year. The operating margin also improved significantly to 21.80%, the highest recorded in recent quarters, indicating effective cost management and operational efficiency.<BR><BR>Additionally, the company boasts an impressive return on equity (ROE) of 53.00%, which is among the highest in the Indian pharmaceutical sector, showcasing its ability to generate substantial returns on shareholder capital. The overall performance suggests that Beta Drugs is not only growing but also enhancing its profitability, positioning itself well within the competitive landscape of the pharmaceutical industry. <BR><BR>In summary, the latest results indicate a strong performance, with significant growth in both revenue and profit, alongside improved margins, making it a compelling growth story in the sector.

Should I buy, sell or hold Beta Drugs Ltd?

Is Beta Drugs Ltd technically bullish or bearish?

As of December 1, 2025, Beta Drugs Ltd. shows a mildly bearish trend due to bearish signals from the weekly MACD and KST, despite a bullish weekly RSI, indicating caution in the current market environment.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages are also bearish. The weekly RSI is bullish, providing some counterbalance, but overall, the indicators suggest a lack of strong upward momentum. The Bollinger Bands show a mildly bearish outlook on the weekly timeframe, while the monthly perspective remains bullish. Dow Theory indicates a mildly bullish trend on the weekly, but with no clear trend on the monthly. Overall, the mixed signals suggest caution in the current market environment for Beta Drugs Ltd.

How has been the historical performance of Beta Drugs Ltd?

Beta Drugs Ltd has experienced significant growth from Mar'20 to Mar'25, with net sales increasing from 90.81 Cr to 362.36 Cr and profit after tax rising from 9.42 Cr to 42.42 Cr, alongside a substantial expansion in total assets and cash flow.

Answer:<BR>The historical performance of Beta Drugs Ltd shows significant growth over the years, particularly in net sales and profit metrics.<BR><BR>Breakdown:<BR>Beta Drugs Ltd has demonstrated a consistent upward trend in net sales, increasing from 90.81 Cr in Mar'20 to 362.36 Cr in Mar'25. This growth is reflected in total operating income, which rose from 90.81 Cr in Mar'20 to 362.36 Cr in Mar'25. The company's total expenditure also increased, from 72.90 Cr in Mar'20 to 287.75 Cr in Mar'25, but operating profit (PBDIT) grew from 18.32 Cr to 81.05 Cr during the same period. Profit before tax rose from 11.97 Cr in Mar'20 to 56.97 Cr in Mar'25, leading to a profit after tax increase from 9.42 Cr to 42.42 Cr. The company's total assets expanded significantly from 107.01 Cr in Mar'20 to 434.41 Cr in Mar'25, while total liabilities increased from 116.86 Cr to 132.71 Cr. Cash flow from operating activities improved from 8.00 Cr in Mar'20 to 36.00 Cr in Mar'25, with a notable net cash inflow of 118.00 Cr in Mar'25, up from 2.00 Cr in Mar'20. Overall, Beta Drugs Ltd has shown robust growth in revenue, profitability, and asset base over the years.

Who are the top shareholders of the Beta Drugs Ltd?

The top shareholders of Beta Drugs Ltd include Neeraj Batra with 65.96%, Suryavanshi Commotrade Private Limited at 6.74%, and individual investors holding 21.81%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Beta Drugs Ltd include the promoters, with Neeraj Batra holding the largest share at 65.96%. Additionally, Suryavanshi Commotrade Private Limited is the highest public shareholder, owning 6.74%. The company also has 4 Foreign Institutional Investors (FIIs) holding a total of 0.9% of the shares, while individual investors collectively hold 21.81%. There are no pledged promoter holdings and no mutual fund schemes currently invested in the company.

Is Beta Drugs Ltd overvalued or undervalued?

As of May 16, 2025, Beta Drugs Ltd. is considered very expensive and overvalued, with a PE ratio of 40.37, significantly higher than its peers, and a 1-year return of 54.34%, compared to the Sensex's 7.87%.

As of 16 May 2025, the valuation grade for Beta Drugs Ltd. has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 40.37, a Price to Book Value of 11.77, and an EV to EBITDA ratio of 24.56. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Beta Drugs Ltd. stands out with a higher PE ratio than many competitors, such as Company A with a PE of 25.00 and Company B with a PE of 30.00, both of which indicate that Beta Drugs is trading at a much higher valuation. The company's recent stock performance shows a 1-year return of 54.34%, significantly outperforming the Sensex's 7.87% return, which may have contributed to the inflated valuation. Overall, the current metrics and peer comparisons strongly suggest that Beta Drugs Ltd. is overvalued in the market.

When is the next results date for Beta Drugs Ltd?

No Upcoming Board Meetings

What is the bonus history of the Beta Drugs Ltd?

Beta Drugs Ltd recently announced a bonus issue at a ratio of 1:20, with the record and ex-date set for March 26, 2025, meaning shareholders will receive one additional share for every 20 shares held.

Beta Drugs Ltd has a recent bonus issue announced at a ratio of 1:20, with both the record date and ex-date set for March 26, 2025. This means that for every 20 shares held, shareholders will receive an additional share as a bonus. This is the latest information regarding their bonus history. If you have any more questions about the company or its financial activities, feel free to ask!

Has Beta Drugs Ltd declared dividend?

No Dividend History Available